Abstract: Chimeric antigen  receptor  （ CAR） T  cell  therapy  has  made  revolutionary  progress  in  the  treatment  of hematologic malignancies， particularly  showing  promising  efficacy  in  patients  with  acute  lymphoblastic  leukemia，  diffuse large B⁃cell lymphoma， follicular lymphoma， and multiple myeloma. However， most patients eventually develop resistance to this therapy. The main mechanisms of resistance to CAR⁃T cell therapy include CAR⁃T cell dysfunction， antigen escape， and the immunosuppressive tumor microenvironment. Strategies to overcome these resistance mechanisms include improving T cell function in vivo， optimizing CAR⁃T cell products， and modulating the immunosuppressive tumor microenvironment.

Key words: chimeric  antigen , receptor , T , cell, hematologic  malignancies ,  , resistance, antigen  escape,  ,  ,  tumor microenvironment